Research suggests that aldo-keto reductase family 1B10 (AKR1B10) may play a role in the development of various cancers, including pancreatic carcinoma. The enzyme's overexpression has been linked to oncogenic function in pancreatic cancer, as well as other types of tumors, such as liver and breast cancer. The relationship between AKR1B10 expression and cancer outcomes appears to be complex, with some studies indicating a potential correlation with tumor recurrence and immune microenvironment.